Lost in (Clinical) Translation: Recent Advances in Heparin Neutralization and Monitoring.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
20 12 2019
Historique:
pubmed: 5 11 2019
medline: 3 4 2020
entrez: 5 11 2019
Statut: ppublish

Résumé

The heparin family, which includes unfractionated heparin, low-molecular heparin, and fondaparinux, is a class of drugs clinically used as intravenous blood thinners. To date, issues related to both the reversal of anticoagulation and the blood level determination of the anticoagulant at the point-of-care remain: while the only U.S. Food and Drug Administration (FDA) approved antidote for heparin displays serious efficacy and safety drawbacks, the current assays for heparin monitoring are indirect measurements subject to their own limitations and variations. Herein, we provide an update on the numerous recent chemical approaches to tackle these issues, from which it is clear that some new antidotes and sensors for heparin certainly have the potential to exceed current clinical standards. This review aims to review a field that requires close collaborations between physicians, biologists, and chemists in order to foster advances toward clinical translation.

Identifiants

pubmed: 31682398
doi: 10.1021/acschembio.9b00772
doi:

Substances chimiques

Anticoagulants 0
Metals 0
Polymers 0
Heparin 9005-49-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2512-2526

Auteurs

Benjamin Ourri (B)

Univ. Lyon, Univ. Claude Bernard Lyon 1, ICBMS UMR CNRS 5246 , 43 Boulevard du 11 Novembre 1918 , 69622 Villeurbanne Cedex , France.

Laurent Vial (L)

Univ. Lyon, Univ. Claude Bernard Lyon 1, ICBMS UMR CNRS 5246 , 43 Boulevard du 11 Novembre 1918 , 69622 Villeurbanne Cedex , France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH